Miscellaneous
This year’s Scientific Sessions of the American Diabetes Association was the second in a row to be held virtually. Nevertheless, the conference was still packed with the usual informative symposia and original research we would expect from ADA. We spoke to three of the speakers to discuss the highlights, including: - Professor Anne Peters on STEP, SUSTAIN FORTE and AMPLITUDE-O - Dr Deborah Wexler on GRADE - Professor Francesco Giorgino on the SURPASS programme For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References - The Management of Type 1 Diabetes in Adults — A Consensus Report by the ADA and EASD (draft) - Abstract 101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial - Wilding J, et al. N Engl J Med. 2021 Mar 18;384(11):989 [STEP 1]. - UK Prospective Diabetes Study - Nathan D, et al. Diabetes Care 2013 Aug; 36(8): 2254-2261 [GRADE]. - Rosenstock J, et al. Lancet. 2021 Jun 25;S0140-6736(21)01324-6 [SURPASS-1]. - Frias J P, et al. N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMoa2107519. Online ahead of print [SURPASS-2] - Abstract 78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3) - Abstract 80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5) Disclosures: Prof. Anne Peters declares the following: Participation on an advisory board: Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, Zealand Research Support: Dexcom, Insulet and donated devices from Abbott Diabetes Care Stock Options: Omada Health, Teladoc Dr Deborah Wexler declares the following: Member of data monitoring committee for SOUL and FLOW trials studying semaglutide, a GLP_1 receptor agonist: Novo Nordisk Prof. Francesco Giorgino declares the following: Grants/Research Support recipient: Eli Lilly, Roche Diabetes Care Consultant (Occasional): Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, Sanofi Honorarium recipient: Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, AstraZeneca, Sanofi, Mundipharma Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.